Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
Sponsor: Theravance Biopharma
Listed as NCT02392208, this PHASE4 trial focuses on End-Stage Renal Disease and Stage 5 Chronic Kidney Disease and remains completed. Sponsored by Theravance Biopharma, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE4
-
May 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — May 2017 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Theravance Biopharma
- University of Michigan
For direct contact, visit the study record on ClinicalTrials.gov .